ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2480

Opioid Use Surrounding Diagnosis of Inflammatory Arthritis

Anna Sheahan1, Victor Sloan 1, Jeffrey Stark 2 and Robert Suruki 1, 1UCB Pharma, Raleigh, NC, 2UCB Pharma, Smyrna, GA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: inflammatory arthritis, opioids and diagnosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Although treatment of inflammatory arthritis (IA) has improved, opioid use among patients remains common. A study from Finland showed increases in opioid use leading up to a diagnosis of IA, then a decrease after diagnosis, and that opioid use in axial spondyloarthritis was higher than in other IAs.1 In a study of patients with AS, 44% of patients were using opioids, and 26% of these patients were using only opioids.2 The timing of opioid use surrounding IA diagnosis in the USA is not known. The objective of this study was to describe opioid use in the year preceding and following diagnosis of AS, RA, and PsA.

Methods: This retrospective observational study analyzed USA commercial claims data (IBM® MarketScan®) from patients with an International Classification of Diseases (ICD) 9/10 code for AS, RA, or PsA (index date) between 2010–2017. Three controls, matched on year, age, sex, region, and insurance plan type, were selected for each disease case. Opioid pharmacy claims were examined in a 12-month baseline (BL) and 12-month follow-up (FU) period after index date with further division into 3-month periods. Chronic opioid use was defined as ≥90 cumulative days’ supply in a 12-month period and was assessed separately in BL and FU. Long-term use was defined as ≥1 opioid claim in ≥3 of 4 quarters in FU. Prevalence ratios for long-term opioid use in the disease vs matched control cohorts were calculated for FU.

Results: The study included 12,377 AS, 215,286 RA, and 20,679 PsA patients (Table). In all 3 cohorts, prevalence of opioid exposure was highest in the quarter following (inclusive of) diagnosis, and prevalence of use was higher in all disease vs matched control cohorts for each quarter (Figure 1). Compared to matched controls, prevalence of chronic opioid use was higher in disease cohorts in BL and FU (Table), and prevalence of long-term use in FU was also higher (Figure 2).

Conclusion: Opioid use is common among patients with IA in both the year preceding and the year following diagnosis, peaking at the time of diagnosis. For all IAs, prevalence of opioid claims and long-term opioid use were higher than in matched controls. Although patterns in these data are similar to those seen in Finland, the overall prevalence of any opioid use (in cases and controls) was higher in the USA. The prevalence of long-term opioid use was highest in AS patients compared to matched controls and highest among the 3 IAs, similar to the finding in Finland. The prevalence of opioid use in IA suggests the presence of uncontrolled pain in the period surrounding diagnosis. Given the ineffectiveness of opioids to address the underlying cause of IA, more comprehensive or appropriate treatments such as DMARDs and/or biologics to address the underlying disease should be considered, in accordance with relevant guidelines.

References:
1.
Muilu P. Ann Rheum Dis 2018;77:A156; 2. Sloan V. J Rheum 2019; doi: 10.3899/jrheum.180972.


Disclosure: A. Sheahan, UCB Pharma, 1, 3; V. Sloan, UCB Pharma, 1, 3, Rutgers-Robert Wood Johnson Medical School, 6; J. Stark, UCB Pharma, 1, 3; R. Suruki, UCB Pharma, 1, 3.

To cite this abstract in AMA style:

Sheahan A, Sloan V, Stark J, Suruki R. Opioid Use Surrounding Diagnosis of Inflammatory Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/opioid-use-surrounding-diagnosis-of-inflammatory-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/opioid-use-surrounding-diagnosis-of-inflammatory-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology